Display options
Cite
Joly-Battaglini A, Hammarström C, Stankovic B, et al. Rituximab efficiently depletes B cells in lung tumors and normal lung tissue. F1000Res. 2016;5:38doi: 10.12688/f1000research.7599.1.
Joly-Battaglini, A., Hammarström, C., Stankovic, B., Aamodt, H., Stjärne, J., Brustugun, O. T., Helland, �. �., Øynebråten, I., & Corthay, A. (2016). Rituximab efficiently depletes B cells in lung tumors and normal lung tissue. F1000Research, 538. https://doi.org/10.12688/f1000research.7599.1
Joly-Battaglini, Albane, et al. "Rituximab efficiently depletes B cells in lung tumors and normal lung tissue." F1000Research vol. 5 (2016): 38. doi: https://doi.org/10.12688/f1000research.7599.1
Joly-Battaglini A, Hammarström C, Stankovic B, Aamodt H, Stjärne J, Brustugun OT, Helland Å, Øynebråten I, Corthay A. Rituximab efficiently depletes B cells in lung tumors and normal lung tissue. F1000Res. 2016 Jan 08;5:38. doi: 10.12688/f1000research.7599.1. eCollection 2016. PMID: 27081474; PMCID: PMC4813631.
Copy Download .nbib Format: NLM
Share it on

F1000Res. 2016 Jan 08;5:38. doi: 10.12688/f1000research.7599.1. eCollection 2016.

Rituximab efficiently depletes B cells in lung tumors and normal lung tissue.

F1000Research

Albane Joly-Battaglini, Clara Hammarström, Branislava Stankovic, Henrik Aamodt, Johan Stjärne, Odd Terje Brustugun, Åslaug Helland, Inger Øynebråten, Alexandre Corthay

Affiliations

  1. Tumor Immunology group, Department of Pathology, Oslo University Hospital, Oslo, Norway; Centre for Immune Regulation, University of Oslo, Oslo, Norway.
  2. Department of Pathology, Oslo University Hospital, Oslo, Norway.
  3. Tumor Immunology group, Department of Pathology, Oslo University Hospital, Oslo, Norway; Centre for Immune Regulation, University of Oslo, Oslo, Norway; Department of Cardiothoracic Surgery, Oslo University Hospital, Oslo, Norway.
  4. Betanien Hospital, Skien, Norway.
  5. Department of Oncology, Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway.
  6. Department of Oncology, Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway; Department of Cancer Genetics, Institute for Cancer Research, Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway.
  7. Tumor Immunology group, Department of Pathology, Oslo University Hospital, Oslo, Norway; Centre for Immune Regulation, University of Oslo, Oslo, Norway; Department of Biosciences, University of Oslo, Oslo, Norway.

PMID: 27081474 PMCID: PMC4813631 DOI: 10.12688/f1000research.7599.1

Abstract

Rituximab is a monoclonal antibody that targets the CD20 B-cell-specific antigen and is widely used as therapy for B-cell lymphoma. Since rituximab depletes both malignant and normal B cells, it is increasingly being used to treat various conditions in which normal B cells have a pathogenic role, such as rheumatoid arthritis and multiple sclerosis. It is well-established that rituximab efficiently eliminates B cells in blood, lymph nodes, and spleen. In contrast, the effect of rituximab in non-lymphoid tissues remains poorly documented and is debated. Here, we report a rheumatoid arthritis patient who was treated with rituximab before receiving thoracic surgery for non-small cell lung cancer. Using flow cytometry and immunohistochemistry, we show that rituximab efficiently depleted CD20-positive B cells in a primary lung tumor, in lung-associated lymph nodes, and in normal lung tissue. We conclude that rituximab may be very efficient at depleting normal B cells in the lungs. This property of rituximab may potentially be exploited for the treatment of conditions in which pathogenic B cells reside in the lungs. On the other hand, the clearance of lung B cells may provide an explanation for the rare cases of severe non-infectious pulmonary toxicity of rituximab.

Keywords: B cells; depletion; lungs; lymph node; monoclonal antibody; non-small cell lung cancer; rituximab; tumor

References

  1. Blood. 1994 Oct 15;84(8):2457-66 - PubMed
  2. Respir Med. 2012 Apr;106(4):581-7 - PubMed
  3. Arthritis Rheum. 2009 Nov;60(11):3251-6 - PubMed
  4. Rheumatology (Oxford). 2012 Apr;51(4):653-62 - PubMed
  5. Blood. 1994 Jan 15;83(2):435-45 - PubMed
  6. Arch Neurol. 2010 Jun;67(6):707-14 - PubMed
  7. N Engl J Med. 2004 Jun 17;350(25):2572-81 - PubMed
  8. Pediatr Pulmonol. 2009 Sep;44(9):922-34 - PubMed
  9. Front Immunol. 2014 May 12;5:197 - PubMed
  10. Arthritis Rheum. 2007 May;56(5):1464-77 - PubMed
  11. Rheumatology (Oxford). 2010 Feb;49(2):271-80 - PubMed
  12. Blood. 2011 Oct 20;118(16):4394-400 - PubMed
  13. N Engl J Med. 2010 Jul 15;363(3):221-32 - PubMed
  14. J Immunol. 2014 Aug 15;193(4):1519-24 - PubMed
  15. N Engl J Med. 2008 Feb 14;358(7):676-88 - PubMed
  16. J Neuroimmunol. 2006 Nov;180(1-2):63-70 - PubMed
  17. Am J Respir Crit Care Med. 2014 Apr 1;189(7):832-44 - PubMed
  18. Oncoimmunology. 2012 Oct 1;1(7):1146-1155 - PubMed
  19. Am J Clin Pathol. 2008 Oct;130(4):604-12 - PubMed
  20. Arthritis Rheum. 2007 Dec;56(12):3909-18 - PubMed
  21. Arthritis Rheum. 2007 Mar;56(3):772-8 - PubMed
  22. Blood. 1997 Sep 15;90(6):2188-95 - PubMed
  23. Ann Rheum Dis. 2008 Mar;67(3):402-8 - PubMed
  24. Arthritis Rheum. 2003 Feb;48(2):455-9 - PubMed
  25. PLoS One. 2015 Jul 01;10(7):e0129898 - PubMed
  26. J Clin Oncol. 2003 Nov 1;21(21):3940-7 - PubMed
  27. Medicine (Baltimore). 2014 Dec;93(27):e229 - PubMed

Publication Types